Asymptomatic and treatment-requiring multiple myeloma - Data from the czech registry of monoclonal gammopathies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R3H" target="_blank" >RIV/61988987:17110/17:A1801R3H - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/17:10365699 RIV/00216208:11150/17:10365699 RIV/00179906:_____/17:10365699 RIV/00843989:_____/17:E0106563 a 2 dalších

Výsledek na webu

<a href="http://dx.doi.org/10.14735/amko20172S51" target="_blank" >http://dx.doi.org/10.14735/amko20172S51</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14735/amko20172S51" target="_blank" >10.14735/amko20172S51</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Asymptomatic and treatment-requiring multiple myeloma - Data from the czech registry of monoclonal gammopathies

Popis výsledku v původním jazyce

Background: Monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma (SMM) are premalignant stages of multiple myeloma (MM). MM is a malignancy of plasma cells, which is associated with a median over all survival of 5 to 7 years. MM accounts for approximately 10% of hematological malignancies. Patients and Methods: Descriptive analysis of data from 19 Czech centres collected in the Registry of Monoclonal Gammopathies(RMG) was performed. Results: Over the last 10 years of prospective collection of data, together with retrospectively recorded data on patients diagnosed before the registry establishment, data on 7,467 patients with either asymptomatic or symptomatic form of MM have been gathered. Validation criteria for the analysis were met by 2,506 MGUS patients, 400 SMM patients and 4,738 MM patients. The median duration of follow-up was 4.3 years in MGUS patients and 2.4 years in SMM patients. The over all risk of progression from MGUS to malignancy was 1.7% per year. The risk of progression from SMM to MM was highest in the 1st years after diagnosis: Over all, this risk was 16.6% per year. The median duration of follow-up was 2.8 years in MM patients. The median over all survival from the diagnosis was 5.7 years. The median OS from treatment initiation/progression-free survival decreased from 60.5/21.0 months in the 1st line therapy to 34.3/12.4 months in the 2nd line therapy, 22.6/8.9 months in the 3rd line therapy and 13.8/5.8 months in the 4th or higher line therapies. Thanks to the availability of novel drugs for MM treatment in the Czech Republic, treatment strategies have changed dramatically over the last decade. Conclusion: RMG is a registry designated for the collection of data on diagnosis, treatment, treatment results and survival of patients with monoclonal gammopathies in the long-term follow-up. RMG is a valuable source of data from real clinical practice.

Název v anglickém jazyce

Asymptomatic and treatment-requiring multiple myeloma - Data from the czech registry of monoclonal gammopathies

Popis výsledku anglicky

Background: Monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma (SMM) are premalignant stages of multiple myeloma (MM). MM is a malignancy of plasma cells, which is associated with a median over all survival of 5 to 7 years. MM accounts for approximately 10% of hematological malignancies. Patients and Methods: Descriptive analysis of data from 19 Czech centres collected in the Registry of Monoclonal Gammopathies(RMG) was performed. Results: Over the last 10 years of prospective collection of data, together with retrospectively recorded data on patients diagnosed before the registry establishment, data on 7,467 patients with either asymptomatic or symptomatic form of MM have been gathered. Validation criteria for the analysis were met by 2,506 MGUS patients, 400 SMM patients and 4,738 MM patients. The median duration of follow-up was 4.3 years in MGUS patients and 2.4 years in SMM patients. The over all risk of progression from MGUS to malignancy was 1.7% per year. The risk of progression from SMM to MM was highest in the 1st years after diagnosis: Over all, this risk was 16.6% per year. The median duration of follow-up was 2.8 years in MM patients. The median over all survival from the diagnosis was 5.7 years. The median OS from treatment initiation/progression-free survival decreased from 60.5/21.0 months in the 1st line therapy to 34.3/12.4 months in the 2nd line therapy, 22.6/8.9 months in the 3rd line therapy and 13.8/5.8 months in the 4th or higher line therapies. Thanks to the availability of novel drugs for MM treatment in the Czech Republic, treatment strategies have changed dramatically over the last decade. Conclusion: RMG is a registry designated for the collection of data on diagnosis, treatment, treatment results and survival of patients with monoclonal gammopathies in the long-term follow-up. RMG is a valuable source of data from real clinical practice.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Klinicka Onkologie

ISSN

0862-495X

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

9

Strana od-do

51-59

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85029541198